Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

1623 - First-in-human study of AC0010, a novel irreversible, mutant-selective EGFR inhibitor in patients with 1st generation EGFR TKI-resistant non-small cell lung cancer (NSCLC)


08 Oct 2016


Developmental therapeutics


Li Zhang


Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368


L. Zhang1, H. Zhao2, B. Hu3, J. Jiang3, X. Zheng3, Y. Zhang2, Y. Ma2, J. Ge2, B. Zou1, X. Fang4, W. Xu4, X. Xu5

Author affiliations

  • 1 State Key Laboratory Of Oncology In South China, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Clinical Trial Center, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
  • 3 Clinical Pharmacology Research Center, Peking Union Medical College Hospital, 100032 - Beijing/CN
  • 4 Acea Biosciences Inc., ACEA Pharmaceutical Research, 310030 - Hangzhou/CN
  • 5 Acea Pharmaceutical Research, ACEA Biosciences Inc., 92121 - San Diego/US


Abstract 1623


AC0010 (Avitinib) is a third generation irreversible EGFR inhibitor. Overcoming T790M-induced resistance by AC0010 has been demonstrated in preclinical studies. This is a first-in-human dose escalation study of AC0010 in EGFR-TKIs resistant patients (NCT02274337).


NSCLC patients with EGFR positive mutation who developed resistance to the 1st generation EGFR TKIs were enrolled including both T790M positive and negative patients. Patients were orally administrated with AC0010 capsules in total 8 dose cohorts: 6 QD dose cohorts (50 mg QD, 100 mg QD, 200 mg QD, 350 mg QD and 550 mg QD), and 3 BID dose cohorts (175 mg BID, 250 mg BID and 300 mg BID). All patients were assessed for pharmacokinetics (PK), overall response rate (ORR), disease control rate (DCR), and adverse events (AEs). Prior to the treatment, biopsy for genotyping was required to confirm T790M status.


As of 5 May 2016, 51 patients (26/25 (49%) female, median age 55, 44/7 (86%) T790M m+) were enrolled. Maximum tolerated dose has not been reached. Most of AEs were grade 1 and transient. Common drug related AEs ≥grade 3 were rash (4%), ALT/AST elevation (4%) and Pneumonia(2%). No hyperglycemia and grade 3 QTc prolongation were observed. PK was dose proportional, median plasma half life was 7.8 (7.6-8.0) hours. BID dosing method could reduce fluctuation coefficient of plasma concentration by 0.40 fold, and improve AUC by 1.28 fold, compared to QD dosing, and no food effects were seen. Among all evaluated patients at the data cut-off, ORR was 41.7% (20/48), and DCR was 75.0% (36/48). Responses were observed at dose levels ≥200mg QD. In AC0010 dose level ≥350mg cohort, the ORR was 57.6% (19/33) and DCR was 87.9% (29/33), and BID dosing schedule had better ORR (66.7% vs 33.3%) and DCR (94.4% vs 77.8%) than QD dosing schedule. The longest duration of response was >11 months at data cut-off.


AC0010 demonstrates a safety profile and promising anticancer activity for NSCLC patients with T790M mutation who develop the resistance to 1st generation TKIs.

Clinical trial identification

NIH(clinicalTrials.gov) number: NCT02274337

Legal entity responsible for the study



ACEA Pharmaceutical Research, Hangzhou, China, and ACEA Biosciences Inc. San Diego, USA.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings